The following is a press release from University of Pittsburgh School of Medicine, UPMC Hillman Cancer Center, and Magee-Womens Research Institute PITTSBURGH, Nov. 12, 2021 – Immune checkpoint inhibitors are a type of cancer treatment that help the immune system’s T cells recognize and attack tumors. But these immunotherapy drugs aren’t effective against all cancers. In … Continued
Have we got a roundup in store! You heard from us a lot in September (thanks to you, we surpassed our Ovarian Cancer Awareness Month fundraising goal!) and there’s still so much to report … research progress, a brand new clinical trial initiative, our upcoming Fall Advocacy Day, and the list goes on. Read on … Continued
November 15-16, 2021 | Register Today! Are you passionate about issues affecting the ovarian cancer community? Now is your chance to have your voice heard at the highest levels — without ever leaving home! OCRA’s Virtual Advocacy Day is a rare opportunity to communicate directly with your Members of Congress, and advocate for federal programs … Continued
Sridevi Challa, PhD, an OCRA grantee at UT Southwestern, is on the receiving end of some major accolades. She is the lead author of a study that dozens of news outlets are describing as having found the “Achilles’ Heel” of ovarian cancer cells. This opens the door for new research in biomarkers and the development … Continued
OCRA grantee Dr. Sumegha Mitra of Indiana University and colleagues have identified the mechanism by which a specific deubiquitinating enzyme known as UCHL1 promotes the growth of high-grade serous ovarian cancer in some patients. This discovery may aid in the development of future ovarian cancer therapies, as it points to the potential effectiveness of a targeted inhibitor … Continued
LOS ANGELES – (BUSINESS WIRE)–Global Coalition for Adaptive Research (GCAR) announces a new clinical trial initiative, Ovarian CanceRxTM. This innovative trial, referred to as an adaptive platform trial, is designed to test multiple drugs simultaneously against the standard of care treatments to rapidly test and deliver new therapies to patients with advanced ovarian cancer or recurrent … Continued
OCRA is conducting a survey to gauge patient response to the expansion of telehealth in response to the pandemic. Since the onset of the COVID-19 pandemic, telehealth has been growing in popularity. Telehealth is the practice of caring for patients remotely when the provider and patient are not physically present with each other. Telehealth can refer to … Continued
As we count down to Ovarian Cancer Awareness Month and our virtual National Conference, there are so many ways to get involved … whether by learning more and connecting with others or raising awareness of the disease and vital funds for research. Read on to find out how you can be a voice, and a … Continued
Researchers at UT Southwestern have discovered a potential “Achilles’ heel” in ovarian cancer cells, and a new biomarker that may open up more avenues for targeted therapies. The study, published in the journal Cell, was led by W. Lee Kraus, PhD, Professor of Obstetrics and Gynecology and Pharmacology at UT Southwestern. Sridevi Challa, PhD, a … Continued
Sultry summer days can make anyone feel lazy and daydream of faraway places. But at OCRA, we’re working as hard as ever to fulfill our dream of a day when no one need fear an ovarian cancer diagnosis. Check out all that’s happening and discover ways that you can get involved. RESEARCH ADVOCACY PATIENT SUPPORT … Continued
Your Representative needs to hear from YOU. Please, urge your Representative to cosponsor Johanna’s Law today >> OCRA and the entire ovarian cancer community applaud the action taken on July 13, 2021 by Congresswoman Rosa DeLauro to reauthorize and expand Johanna’s Law. Since it was signed into law in 2007, Johanna’s Law has helped educate … Continued
A long-running study from Dana-Farber Cancer Institute, published in Nature Cancer and co-funded by OCRA, has discovered that the antibiotic novobiocin is capable of targeting and killing tumor cells in laboratory cell lines and tumor models with BRCA1 or BRCA2 genetic mutations–and is effective even in tumors that have become resistant to PARP inhibitors. BRCA1 … Continued
Get email updates about research news, action alerts, and ways to join the fight.
